Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 2, 2007

Diosynth Inks Deal with VGX Pharmaceuticals

  • Diosynth Biotechnology signed an agreement with VGX Pharmaceuticals for process development and production of clinical trial material for the latter’s anticancer candidate.

    VGX Pharmaceuticals says that it has developed technology using specific viral proteins that can induce selective apoptosis in rapidly dividing cancer cells, leaving normal cells unharmed. VGX-100, a recombinant viral protein r (Vpr), induces tumor cell death through apoptosis in a number of human-derived tumor tissues, including breast, prostate, and brain. Initial clinical trials will target patients with Non-Hodgkin’s lymphoma and gastric cancer.

    The development and manufacturing program that Diosynth Biotechnology will perform employs the Dowpharma Pfenex Expression Technology™, a Pseudomonas-based technology. Pfenex Expression Technology can increase yields of recombinant protein when used in biomanufacturing applications, according to Diosynth.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.